Vaughn H, Major H, Kadera E, Keck K, Dunham T, Qian Q
Int J Mol Sci. 2024; 25(14).
PMID: 39062773
PMC: 11277019.
DOI: 10.3390/ijms25147532.
Postel M, Darabi S, Howe J, Liang W, Craig D, Demeure M
F1000Res. 2023; 12:417.
PMID: 37954063
PMC: 10632590.
DOI: 10.12688/f1000research.130251.2.
Lopez-Garrido M, Carrascosa-Romero M, Montero-Hernandez M, Serrano-Martinez C, Sanchez-Sanchez F
Front Genet. 2022; 13:1005573.
PMID: 36468000
PMC: 9716064.
DOI: 10.3389/fgene.2022.1005573.
Makinen N, Zhou M, Zhang Z, Kasai Y, Perez E, Kim G
Genome Med. 2022; 14(1):82.
PMID: 35922826
PMC: 9351068.
DOI: 10.1186/s13073-022-01083-1.
Duan S, Rico K, Merchant J
Function (Oxf). 2022; 3(1):zqab062.
PMID: 35330921
PMC: 8788842.
DOI: 10.1093/function/zqab062.
EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine.
Barazeghi E, Hellman P, Norlen O, Westin G, Stalberg P
Sci Rep. 2021; 11(1):22733.
PMID: 34815475
PMC: 8611048.
DOI: 10.1038/s41598-021-02181-7.
Genetic Drivers of Ileal Neuroendocrine Tumors.
Carpizo D, Harris C
Cancers (Basel). 2021; 13(20).
PMID: 34680217
PMC: 8533727.
DOI: 10.3390/cancers13205070.
Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors.
Asa S, La Rosa S, Basturk O, Adsay V, Minnetti M, Grossman A
Endocr Pathol. 2021; 32(1):169-191.
PMID: 33459926
DOI: 10.1007/s12022-021-09662-5.
Loss of copy of MIR1-2 increases CDK4 expression in ileal neuroendocrine tumors.
Contractor T, Harris C
Oncogenesis. 2020; 9(3):37.
PMID: 32198354
PMC: 7083839.
DOI: 10.1038/s41389-020-0221-4.
Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies.
Boons G, Vandamme T, Peeters M, Van Camp G, Op de Beeck K
Rev Endocr Metab Disord. 2019; 20(3):333-351.
PMID: 31368038
DOI: 10.1007/s11154-019-09508-w.
Molecular prognostic factors in small-intestinal neuroendocrine tumours.
Samsom K, van Veenendaal L, Valk G, Vriens M, Tesselaar M, van den Berg J
Endocr Connect. 2019; 8(7):906-922.
PMID: 31189127
PMC: 6599083.
DOI: 10.1530/EC-19-0206.
Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms.
Mafficini A, Scarpa A
Endocr Rev. 2019; 40(2):506-536.
PMID: 30657883
PMC: 6534496.
DOI: 10.1210/er.2018-00160.
Establishment, functional and genetic characterization of a colon derived large cell neuroendocrine carcinoma cell line.
Gock M, Mullins C, Harnack C, Prall F, Ramer R, Goder A
World J Gastroenterol. 2018; 24(33):3749-3759.
PMID: 30197480
PMC: 6127660.
DOI: 10.3748/wjg.v24.i33.3749.
Decrease of 5-hydroxymethylcytosine and TET1 with nuclear exclusion of TET2 in small intestinal neuroendocrine tumors.
Barazeghi E, Prabhawa S, Norlen O, Hellman P, Stalberg P, Westin G
BMC Cancer. 2018; 18(1):764.
PMID: 30045709
PMC: 6060499.
DOI: 10.1186/s12885-018-4579-z.
The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors.
Amair-Pinedo F, Matos I, Sauri T, Hernando J, Capdevila J
Target Oncol. 2017; 12(6):757-774.
PMID: 29143176
DOI: 10.1007/s11523-017-0532-3.
A germline mutation is associated with small intestinal neuroendocrine tumors.
Dumanski J, Rasi C, Bjorklund P, Davies H, Ali A, Gronberg M
Endocr Relat Cancer. 2017; 24(8):427-443.
PMID: 28634180
PMC: 5527373.
DOI: 10.1530/ERC-17-0196.
Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology.
Kidd M, Modlin I, Bodei L, Drozdov I
Cell Mol Gastroenterol Hepatol. 2017; 1(2):131-153.
PMID: 28210673
PMC: 5301133.
DOI: 10.1016/j.jcmgh.2014.12.008.
Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection.
Roland C, Starker L, Kang Y, Chatterjee D, Estrella J, Rashid A
Surgery. 2016; 161(3):753-759.
PMID: 27816207
PMC: 5937257.
DOI: 10.1016/j.surg.2016.09.002.
Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms.
Kidd M, Modlin I, Oberg K
Nat Rev Clin Oncol. 2016; 13(11):691-705.
PMID: 27273044
DOI: 10.1038/nrclinonc.2016.85.
A plausible role for actin gamma smooth muscle 2 (ACTG2) in small intestinal neuroendocrine tumorigenesis.
Edfeldt K, Hellman P, Westin G, Stalberg P
BMC Endocr Disord. 2016; 16:19.
PMID: 27107594
PMC: 4841950.
DOI: 10.1186/s12902-016-0100-3.